drug
discoveri
process
profoundli
chang
recent
adopt
comput
method
help
design
new
drug
candid
rapidli
lower
cost
silico
drug
design
consist
collect
tool
help
make
ration
decis
differ
step
drug
discoveri
process
identif
biomolecular
target
therapeut
interest
select
design
new
lead
compound
modif
obtain
better
affin
well
pharmacokinet
pharmacodynam
properti
among
differ
tool
avail
particular
emphasi
place
review
molecular
dock
virtual
highthroughput
screen
fragmentbas
ligand
design
drug
discoveri
interdisciplinari
complex
time
consum
expens
process
wide
admit
pharmaceut
industri
spend
far
research
develop
produc
fewer
new
molecul
year
ago
pricewaterhousecoop
pharma
report
stress
pharmaceut
industri
need
find
mean
improv
effici
effect
drug
discoveri
develop
project
silico
method
becom
domin
tool
address
issu
drug
discoveri
market
recent
advanc
comput
techniqu
hardwar
enabl
silico
method
speed
lead
identif
optim
till
techniqu
contribut
design
compound
enter
clinic
trial
fda
approv
today
silico
drug
design
seen
techniqu
abl
suggest
directli
small
number
compound
high
affin
select
target
macromolecul
along
favour
pharmacokinet
pharmacodynam
properti
use
three
dimension
structur
target
start
point
rather
consist
systemat
use
wide
rang
differ
comput
tool
aim
instanc
improv
knowledg
targetligand
interact
molecular
dock
increas
yield
molecul
screen
focus
search
compound
like
bind
target
virtual
highthroughput
screen
vht
even
suggest
new
potenti
lead
compound
fragmentfragmentbas
ligand
design
fbd
method
detail
molecular
dock
tri
predict
nativ
posit
orient
conform
socal
nativ
pose
nativ
bind
mode
smallmolecul
ligand
within
bind
site
target
macromolecul
provid
basic
understand
interact
take
place
ligand
receptor
dock
open
door
affin
estim
prior
synthesi
well
ligand
optim
techniqu
exampl
fig
show
success
dock
cilengitid
molecul
integrin
surfac
realiz
eadock
pioneer
earli
dock
remain
vigor
research
area
among
use
tool
silico
drug
design
primari
compon
mani
drug
discoveri
program
dock
roughli
describ
combin
search
algorithm
intend
suggest
sever
possibl
ligand
pose
score
function
aim
identifi
true
nativ
bind
mode
number
put
bind
mode
ligand
protein
surfac
virtual
infinit
henc
search
algorithm
fast
effect
cover
relev
conform
space
includ
pose
close
nativ
bind
mode
part
score
function
need
captur
thermodynam
ligandprotein
interact
adequ
distinguish
true
bind
mode
ideal
correspond
global
minimum
function
other
put
one
suggest
search
algorithm
also
fast
enough
treat
larg
number
potenti
solut
differ
dock
program
avail
today
wide
use
autodock
genet
optimis
ligand
dock
gold
flexx
flex
dock
intern
coordin
mechan
icm
icmflex
receptor
dock
algorithm
ifreda
tabl
give
short
descript
repres
program
dock
softwar
differ
way
handl
protein
ligand
flexibl
sampl
algorithm
score
function
aspect
detail
sever
approach
use
sampl
ligandbind
mode
case
treat
flexibl
protein
sampl
algorithm
may
divid
three
major
categori
systemat
search
algorithm
flexx
flex
dock
glide
hammerhead
stochast
method
autodock
gold
quick
explor
qxp
eadock
simul
approach
ideal
systemat
explor
dof
molecul
find
nativ
bind
mode
usual
imposs
task
due
combinatori
explos
search
space
therefor
sever
method
fall
categori
systemat
search
algorithm
use
techniqu
increment
reconstruct
ligand
compens
exponenti
depend
molecular
size
basic
two
way
perform
increment
reconstruct
first
one
flexx
flex
molecul
divid
singl
rigid
fragment
sever
shell
flexibl
extens
rigid
fragment
select
abil
make
highest
number
interact
receptor
dock
first
flexibl
moieti
reconnect
increment
ad
one
flexibl
compon
new
interact
search
complianc
torsion
databas
score
function
use
select
best
partial
solut
use
next
extens
step
second
variant
increment
reconstruct
hammerhead
origin
version
dock
molecul
decompos
variou
fragment
dock
independ
subsequ
fuse
activ
site
use
hingebend
algorithm
addit
reconstruct
algorithm
program
approxim
complet
systemat
search
bind
mode
space
ligand
narrow
latter
use
sever
filter
instanc
glide
perform
initi
rough
posit
score
phase
narrow
search
space
follow
torsion
flexibl
energi
optim
hundr
surviv
candid
pose
best
candid
refin
via
mont
carlo
mc
sampl
pose
conform
improv
accuraci
stochast
method
ligand
consid
whole
stepbystep
chang
appli
start
pose
popul
pose
method
subsequ
score
new
pose
step
tri
enhanc
interact
protein
lead
hope
nativ
bind
mode
evolutionari
algorithm
ea
mc
simul
fall
categori
ea
mimic
process
darwinian
evolut
start
point
collect
pose
correspond
plausibl
ligandreceptor
complex
also
call
start
popul
seed
object
function
assign
score
bind
mode
less
like
replac
new
one
form
novel
gener
new
pose
gener
via
comput
procedur
call
oper
mimic
biolog
mutat
crossov
mutat
introduc
perturb
bind
mode
like
rotat
one
dihedr
angl
crossov
combin
two
pose
oper
appli
pose
select
fittest
element
popul
hope
even
fitter
solut
gener
algorithm
end
given
number
gener
energi
evalu
converg
solut
bestknown
program
categori
gold
autodock
sever
new
promis
eabas
algorithm
emerg
like
eadock
moldock
program
vari
way
handl
pose
oper
score
function
reader
refer
relev
paper
detail
descript
method
mcbase
method
start
singl
randomli
gener
pose
appli
subsequ
random
move
like
rotat
one
dihedr
angl
global
translat
rotat
whole
ligand
modif
new
pose
score
metropoli
criterion
appli
choos
whether
new
pose
retain
start
point
next
modif
algorithm
continu
previou
one
algorithm
end
similarli
eabas
approach
exampl
qxp
program
belong
categori
simul
method
group
molecular
dynam
minim
method
approach
often
unabl
cross
highenergi
barrier
within
feasibl
simul
time
period
therefor
might
accommod
ligand
local
minima
energi
surfac
consequ
rare
employ
standalon
search
techniqu
howev
effici
complement
search
method
refin
local
pose
suggest
one
mc
eabas
step
like
autodock
dock
eadock
score
function
typic
implement
proteinligand
dock
divid
three
major
categori
knowledgebas
empir
forcefieldbas
score
function
knowledgebas
score
function
use
interatom
interact
potenti
obtain
reverseboltzmann
analysi
occurr
differ
atomatom
pair
contact
known
experiment
complex
structur
empir
score
function
base
idea
bind
free
energi
written
weight
sum
uncorrel
term
hydrogen
bond
nonpolar
aromat
contact
entropi
penalti
weight
factor
term
determin
regress
analysi
use
proteinligand
complex
known
experiment
bind
free
energi
structur
although
easi
fast
method
suffer
limit
descript
physic
aspect
bind
process
depend
experiment
dataset
use
parameter
contrari
estim
bind
free
energi
forc
fieldbas
method
use
unfit
univers
physic
sound
energi
function
van
der
waal
electrostat
interact
energi
intramolecular
energi
recent
implicit
solvat
model
introduc
dock
score
captur
solvent
effect
upon
associ
dock
program
gener
approxim
exact
forcefield
energi
use
grid
summat
interact
energi
protein
atom
sampl
calcul
differ
regularli
space
point
bind
energi
ligand
calcul
sum
contribut
grid
point
occupi
small
molecul
take
account
actual
natur
charg
ligand
atom
eadock
among
dock
program
make
direct
use
univers
detail
forc
field
accur
solvat
model
gener
born
use
molecular
volum
perform
dock
program
gener
assess
redock
calcul
first
hundr
thousand
experiment
determin
repres
ligandprotein
complex
collect
like
ligandprotein
databas
astexcambridg
crystallograph
data
centr
ccdc
astexdivers
set
mother
databas
ligand
remov
bind
site
abil
program
reproduc
nativ
bind
mode
assess
gener
dock
consid
success
root
mean
squar
deviat
rmsd
experiment
calcul
bind
mode
lower
although
current
standard
definit
arguabl
sinc
shown
two
bind
mode
within
rmsd
make
differ
interact
protein
sever
benchmark
differ
dock
algorithm
avail
show
typic
success
rate
redock
rang
depend
author
test
set
import
note
figur
overestim
effici
program
typic
drug
design
studi
inde
redock
process
neglect
inducedfit
issu
protein
conform
use
dock
given
ligand
come
experiment
structur
complex
thu
adapt
fit
particular
compound
case
ligand
taken
screen
databas
design
silico
method
recent
confirm
dock
ligand
nonn
protein
conform
ie
perform
call
crossdock
difficult
task
success
rate
dock
program
reduc
least
howev
progress
might
expect
method
develop
handl
protein
flexibl
fast
effici
way
sever
analys
also
shown
perform
dock
softwar
highli
depend
particular
characterist
bind
site
ligand
hardli
possibl
figur
priori
method
combin
search
algorithm
score
function
suit
particular
studi
high
throughput
screen
ht
typic
use
earli
stage
drug
design
process
order
test
larg
compound
collect
potenti
activ
chosen
target
unfortun
ht
time
consum
costli
reason
comput
corollari
vht
becom
import
tool
preced
larg
vitro
screen
assay
perform
pharmaceut
compani
vht
aim
use
comput
tool
estim
priori
entir
databas
exist
compound
compound
could
made
like
affin
target
basic
two
approach
topic
ligandand
structurebas
vht
structur
target
unknown
measur
activ
known
compound
use
construct
pharmacophor
model
latter
summar
posit
key
featur
like
hydrogenbond
hydrophob
group
match
put
ligand
model
use
templat
select
promis
candid
librari
strategi
also
use
filter
appli
structurebas
vht
initi
databas
final
dock
structurebas
vht
probabl
straightforward
applic
dock
algorithm
consist
use
molecular
dock
program
determin
bind
mode
protein
target
entir
databas
exist
virtual
compound
bound
conform
use
approxim
bind
free
energi
relat
affin
compound
promis
compound
retain
experiment
test
wide
use
dock
program
vht
dock
flexx
glide
gold
autodock
size
librari
use
approach
rang
hundr
thousand
million
compound
limit
time
avail
dock
minut
less
size
databas
trade
number
molecul
treat
reason
amount
time
chemic
space
desir
cover
despit
steadi
improv
comput
hardwar
conform
sampl
therefor
limit
vht
suffer
lot
fals
neg
despit
vast
amount
resourc
invest
ht
vht
sever
success
studi
outcom
term
new
compound
reach
clinic
might
seen
rather
disappoint
test
experiment
hit
molecular
fragment
exhibit
gener
weak
affin
order
mm
howev
provid
interest
start
point
followup
strategi
tri
connect
sever
give
new
effici
lead
compound
fragmentbas
design
perform
silico
experiment
use
nuclear
magnet
reson
nmr
xray
crystallographi
review
focu
silico
approach
fbd
sever
theoret
advantag
vht
first
fbd
sampl
higher
chemic
divers
ht
inde
ht
chemic
librari
typic
contain
although
huge
effort
handl
amount
molecul
experiment
even
silico
cover
tini
amount
chemic
space
access
small
druglik
molecul
sever
studi
estim
number
around
far
beyond
test
vht
even
largest
possibl
effort
could
imagin
nowaday
use
estim
million
compound
avail
worldwid
scratch
surfac
chemic
space
contrari
fbd
allow
sampl
much
larger
amount
chemic
divers
use
much
smaller
number
start
molecul
illustr
chemic
space
molecul
obtain
connect
combinatori
three
fragment
belong
databas
contrarili
ht
requir
one
virtual
experiment
assay
per
fragment
molecul
construct
promis
one
also
calcul
number
stabl
synthet
access
molecular
fragment
around
number
nearli
order
magnitud
test
ht
cover
much
vaster
part
chemic
space
second
fbd
lead
higher
hit
rate
illustr
fact
probabl
bad
ligandprotein
interact
increas
exponenti
size
complex
molecul
consequ
probabl
small
simpl
molecul
bind
protein
even
low
affin
much
higher
htssize
compound
probabl
climb
simpl
fragment
support
use
molecular
fragment
anchor
drug
design
process
rather
complex
larg
molecul
final
fbd
lead
molecul
higher
ligand
effici
ht
chemic
librari
compos
complex
molecul
origin
develop
purpos
bind
current
target
consequ
even
ht
hit
expect
form
suboptim
bind
interact
target
contrari
due
size
high
proport
atom
fragment
hit
directli
involv
proteinbind
interact
optim
thu
better
probabl
lead
effici
therefor
smaller
drug
fig
better
chanc
favour
pharmacokinet
properti
interestingli
bind
free
energi
molecul
result
optim
link
two
fragment
expect
lower
thu
favour
sum
free
energi
bind
two
isol
fragment
see
fig
result
fact
rigid
bodi
entrop
loss
upon
bind
molecul
larg
wherea
entrop
penalti
associ
freez
rotat
bond
small
circumst
rigid
bodi
entrop
loss
upon
bind
one
molecul
due
freez
dof
three
rigid
translat
three
rigid
rotat
small
molecul
properti
fragment
hit
identifi
experiment
sever
target
indic
show
averag
properti
consist
rule
three
ie
molecular
weight
gmol
number
hydrogenbond
donor
number
hydrogenbond
acceptor
calcul
logp
addit
found
number
rotat
bond
polar
surfac
area
usual
lower
equal
respect
fragment
usual
obtain
use
chemoinformat
approach
break
biolog
activ
compound
limit
number
fragment
depend
definit
molecular
fragment
use
chemic
space
druglik
molecul
reduc
hundr
thousand
fragment
sever
approach
avail
automat
decompos
molecul
rigid
fragment
sever
method
develop
silico
fbd
see
tabl
differ
build
block
use
construct
ligand
atom
fragment
target
constraint
appli
ligandor
receptorbas
strategi
use
sampl
chemic
space
depth
first
breadth
first
mc
ea
structur
sampl
mainli
grow
link
random
structur
mutat
score
function
use
rank
put
ligand
among
repres
method
one
find
ludi
multicopi
simultan
search
mcss
hook
proligand
small
molecul
growth
smog
dewitt
shakhnovich
ligbuild
leapfrog
tripo
inc
tripo
st
loui
mo
usa
ccld
genet
algorithmbas
de
novo
design
inhibitor
gandi
ligandbas
fbd
new
molecul
design
base
exist
ligand
latter
differ
constraint
score
function
deriv
like
pharmacophor
model
molecular
similar
quantit
structur
activ
relationship
qsar
score
function
contrari
receptorbas
fbd
use
structur
protein
bind
site
design
molecul
expect
optim
ligandprotein
interact
sever
score
function
call
primari
constraint
use
rank
suggest
molecul
drive
search
chemic
space
correspond
mainli
use
dock
program
ie
forc
fieldbas
empir
knowledgebas
score
function
addit
sever
physicochem
paramet
relat
druglik
compound
well
term
account
molecular
spatial
similar
known
ligand
use
filter
ad
score
function
latter
call
secondari
constraint
link
approach
fig
start
placement
build
block
key
interact
site
receptor
done
fragmentbas
design
softwar
use
dedic
softwar
like
mcss
solvat
energi
exhaust
dock
seed
eadock
latter
particularli
suit
fragmentbas
approach
sinc
thank
clusterbas
sampl
algorithm
univers
applic
score
function
abl
map
fragment
favour
posit
dock
complet
molecul
posit
fragment
automat
connect
use
linker
result
sever
complet
molecul
satisfi
key
interact
site
contrari
grow
procedur
fig
start
singl
fragment
locat
one
key
interact
site
target
fragment
chosen
user
program
structur
grown
first
fragment
iter
piecebypiec
addit
made
yield
favour
interact
target
new
fragment
keep
alreadi
shown
start
molecul
connect
rule
deriv
exist
certain
bond
organ
compound
organ
synthesi
reaction
grow
link
strategi
strength
weak
grow
might
run
difficulti
activ
site
contain
sever
distinct
pocket
separ
larg
gap
interact
ligand
protein
limit
use
link
approach
slightli
misplac
fragment
fragment
loos
defin
spatial
orient
like
phenyl
ring
prefer
orient
larg
lipophil
bind
pocket
lead
construct
suboptim
molecul
expect
ab
initio
fbd
yield
nanomolar
compound
first
instanc
rather
method
probabl
design
new
perspect
lead
compound
medium
affin
start
point
optim
howev
fbd
techniqu
alreadi
contribut
gener
impress
number
high
affin
ligand
drug
lead
clinic
trial
although
recent
adopt
drug
discoveri
pipelin
fbd
repres
promis
techniqu
address
tomorrow
challeng
drug
discoveri
result
search
provid
commerci
avail
molecul
thu
synthesi
like
describ
optim
also
possibl
assess
synthet
access
candid
compound
addit
softwar
attempt
defin
synthet
rout
select
potenti
precursor
databas
avail
compound
similarli
score
function
establish
recent
tri
mimic
intuit
organ
chemist
estim
synthet
feasibl
molecul
examin
chemic
structur
without
suggest
retrosynthesi
brief
outlin
common
type
silico
tool
present
emphas
great
progress
silico
drug
design
made
great
chang
past
year
make
valuabl
effici
tool
drug
discoveri
despit
numer
success
studi
posit
pictur
often
drawn
dock
problem
far
solv
molecular
dock
still
hold
sever
limit
like
lack
univers
applic
score
function
abl
effici
combin
accuraci
speed
sever
direct
improv
investig
like
use
implicit
solvent
model
entrop
term
addit
although
ligand
commonli
handl
full
flexibl
protein
flexibl
still
partial
consid
best
studi
still
necessari
tackl
issu
address
inducedfit
problem
also
dynam
inclus
water
molecul
dock
process
take
account
eventu
import
watermedi
hydrogen
bond
bridg
ligand
protein
could
increas
effici
approach
today
result
dock
experi
taken
care
seen
good
start
point
involv
studi
sever
studi
illustr
abil
vht
suggest
put
lead
compound
help
experiment
counterpart
reduc
drastic
number
molecul
effect
test
howev
despit
larg
effort
deploy
outcom
term
new
compound
reach
clinic
trial
might
seen
rather
disappoint
fig
influenc
fragment
link
experiment
affin
fbd
studi
target
avidin
structurebas
fbd
could
also
benefit
better
treatment
flexibl
target
protein
improv
bind
free
energi
estim
method
howev
autom
de
novo
design
particular
fbd
alreadi
proven
valu
hit
leadstructur
identif
silico
design
molecul
provid
medicin
chemist
ration
support
guid
idea
valuabl
new
chemic
entiti
thu
help
develop
novel
patent
lead
